Comparison of nedapaltin and cispaltin chemotherapy combined with intensity modulated radiotherpy for locally advanced nasopharygeal carcinoma patients in unendemic area
10.3760/cma.j.issn.0254-5098.2018.11.007
- VernacularTitle:奈达铂对比顺铂化疗联合IMRT治疗非高发区局部晚期鼻咽癌临床观察
- Author:
Xueming SUN
1
;
Hui WU
;
Xiaoxu LU
;
Jing XU
;
Shujuan WANG
;
Xinyu CHENG
;
Zhumin YAN
;
Rong HUANG
Author Information
1. 450008,郑州大学附属肿瘤医院 河南省肿瘤医院放疗科
- Keywords:
Nasopharygeal neoplasms;
Concurrent chemoradiotherapy;
Intensity-modulated radiotherapy;
Adjuvant chemotherapy;
Prognosis
- From:
Chinese Journal of Radiological Medicine and Protection
2018;38(11):836-841
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy and toxicity of nedaplatin and cispaltin chemotherapy combined with intensity modulated radiotherpy ( IMRT) in the treatment of locally advanced nasopharygeal carcinoma (NPC) patients in unendemic area. Methods From January 2014 to July 2016, sixty-two pairs of patients with stageⅢ-ⅣB NPC patients who underwent radical radiotherapy were selected for pair analysis (nedaplatin group and cisplatin group, 62 cases for each group). The nedaplatin group was treated with IMRT concurrent with nedaplatin at a dose of 100 mg/m2 every three-weeks for 2 -3 cycles, and sequential adjuvant chemotherapy of nedaplatin + fluorouracil regimen for 2 to 3 courses. The cisplatin group was treated with IMRT concurrent with cisplatin at a dose of 80 mg/m2 every three-weeks for 2-3 cycles, and sequential adjuvant chemotherapy of cisplatin + fluorouracil regimen for 2 to 3 courses. Results The 2-year overall survival ( OS ) of nedaplatin group and cisplatin group was 89. 9％ and 91. 1％, local recurrence free survival ( LRFS ) 90. 5％ and 93. 5％, regional recurrence free survival ( RRFS ) 96. 4％ and 96. 0％, and distant metastasis free survival ( DMFS ) 85. 9％ and 90. 3％, respectively. There were no significant differences between nedaplatin group and cisplatin group ( P >0. 05 ) . In the occurrence of acute toxicity, during concurrent chemoradiotherapy and adjuvant chemotherapy, the incidence of grade 3-4 vomiting in nedaplatin group was significantly lower than that in cisplatin group. During adjuvant chemotherapy, the incidence of grade 3 - 4 thrombocytopenia in nedaplatin group was significantly higher than that in cisplatin group. Conclusions For NPC patients with stage Ⅲ-ⅣB in unendemic area, the 2-year survival rates of nedaplatin group was silimiar to cisplatin group, while the incidence of grade 3 -4 vomiting was significantly lower than that in cisplatin group. Nedaplatin maybe an alternative chemotherapy for patients who cannot tolerate cisplatin chemotherapy.
